Discontinuation of Infliximab Therapy in Patients With Crohn's Disease During Sustained Complete Remission: A Multi-center, Double Blinded, Randomized, Placebo Controlled Study
Latest Information Update: 25 Mar 2022
At a glance
- Drugs Infliximab (Primary)
- Indications Crohn's disease
- Focus Therapeutic Use
- Acronyms STOP IT
- 11 Oct 2021 Status changed from recruiting to completed.
- 04 Oct 2020 This trial is completed in Sweden (Global End Date: 30 Apr 2020), according to European Clinical Trials Database record.
- 30 Aug 2020 This trial has been completed in Denmark and Norway (Date of the global end of the trial: 30 Apr 2020).